OpenAI Expands Daybreak Access for Governed Cybersecurity Work
11 August 20266 min read
Medicine
JAMA Trial Finds Longer Progression-Free Survival With Osimertinib-Chemotherapy Combination
A randomized phase 3 JAMA trial in EGFR-mutated advanced non-small cell lung cancer with concurrent TP53 mutations found longer progression-free survival with first-line osimertinib plus chemotherapy than with osimertinib alone.
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
JAMA published a randomized phase 3 study online on 10 August 2026 comparing first-line osimertinib plus chemotherapy with osimertinib monotherapy in patients with EGFR-mutated advanced non-small cell lung cancer and concurrent TP53 mutations.
The open-label multicentre study enrolled 294 eligible patients at 17 sites in China between March 2021 and July 2024. Participants were randomized to osimertinib plus pemetrexed and carboplatin followed by maintenance osimertinib plus pemetrexed, or to osimertinib alone.
At median follow-up of about 25 months in the combination group and 26 months in the monotherapy group, median progression-free survival was 34.0 months with combination therapy versus 15.6 months with osimertinib alone. JAMA reports a hazard ratio for disease progression or death of 0.44 with a 95% confidence interval of 0.32 to 0.60 and P < .001.
The authors report immature overall-survival data, with a trend toward benefit, and a higher incidence of grade 3 or higher treatment-related adverse events in the combination group. They reported no new safety signal.
The trial supports TP53-based molecular risk stratification for a high-risk subset of EGFR-mutated NSCLC, but it does not settle overall-survival benefit or generalizability outside the studied population and setting.
Why It Matters
Precision oncology is moving beyond single driver mutations toward co-mutation risk profiles. If validated across broader populations, TP53 status could help decide which patients should accept the added burden of chemotherapy with first-line targeted therapy.
Sourcing note: Confirmed facts are the JAMA publication date, trial registration, enrolled population, treatment arms and published efficacy and safety results. The paper is peer reviewed, but it was open-label, conducted in China, and overall-survival results were immature at the data cutoff.
Why It Matters
The study offers prospective evidence that a molecularly defined high-risk subgroup may benefit from intensified first-line therapy. The trade-off is toxicity and treatment burden, so mature survival data and external validation matter before this becomes a broad default.
What to Watch
Watch for mature overall-survival results, guideline updates, replication outside China, quality-of-life details and whether testing workflows routinely capture TP53 status before first-line EGFR treatment decisions.
Primary Sources
Our sourcing: Cedar S. Insights reports from primary sources — official announcements, peer-reviewed research, regulatory filings and verified company statements. We do not publish unverified rumours.
Corrections: If you believe any detail in this article is inaccurate, please contact [email protected] with the specific claim and supporting evidence. Verified corrections are applied promptly and noted in the article.
Topics
JAMALung CancerOsimertinibPrecision Medicine